請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73508
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳玉怜(YUH-LIEN CHEN) | |
dc.contributor.author | Ming-Hsien Chiang | en |
dc.contributor.author | 江明憲 | zh_TW |
dc.date.accessioned | 2021-06-17T07:38:59Z | - |
dc.date.available | 2024-08-26 | |
dc.date.copyright | 2019-08-26 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-03-05 | |
dc.identifier.citation | 參考資料
Abbate A, Bussani R, Amin MS, Vetrovec GW, Baldi A: Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol 2006; 38:1834-1840. Ahlin F, Arfvidsson J, Vargas KG, Stojkovic S, Huber K, Wojta J: MicroRNAs as circulating biomarkers in acute coronary syndromes: A review. Vascul Pharmacol 2016;81:15-21. Ahmadi A, Behmanesh M, Boroumand MA, Tavallaei M: Up-regulation of MSH2, XRCC1 and ATM genes in patients with type 2 diabetes and coronary artery disease. Diabetes Res Clin Pract 2015;109:500-506. Assunção Guimarães C, Linden R.: Programmed cell deaths Apoptosis and alternative deathstyles. Eur J Biochem 2004;271:1638–1650. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-1677. Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A.: Atm selectively regulates distinct p53- dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 1997;17:453–456. Bencokova Z, Kaufmann MR, Pires IM, Lecane PS, Giaccia AJ, Hammond EM.: ATM activation and signaling under hypoxic conditions. Mol. Cell Biol 2009;29:526–537. Bilal M, Haseeb A, Khan MA: Circulation of miR-26a, miR-191, and miR-208b in plasma of patients with acute myocardial infarction. J Pak Med Assoc 2016;66:125. Bin-Dayel AF, Abdel Baky NA, Fadda LM, Mohammad RA, Al-Mohanna F: Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. Toxicol Mech Methods. 2016; 26:122-131. Chen CY, Chang JT, Ho YF, Shyu AB.: MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1. Nucleic Acids Res 2016; 44:3772-87. Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, Lu PH: Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 2011;226:1915-1925. Chen X, Xiao W, Chen W, Liu X, Wu M, Bo Q, Luo Y, Ye S, Cao Y, Liu Y:. MicroRNA-26a and -26b inhibit lens fibrosis and cataract by negatively regulating Jagged-1/Notch signaling pathway. Cell Death Differ 2017; 24:1431-1442. Cokkinos DV, Pantos C.: Myocardial protection in man: from research concept to clinical practice. Heart Fail Rev 2007; 12:345–362. Daugherity EK, Balmus G, Al Saei A, Moore ES, Abi Abdallah D, Rogers AB, Weiss RS, Maurer KJ: The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle 2012; 11:1918-1928. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 2003; 4(5):P3. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, Corsten MF, Schroen B, Lair ML, Heymans S, Wagner DR: Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 2012; 58:559-567. Elmore S.: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516. Espira L, Czubryt MP.: Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol 2009; 87:996–1008. Faccini J, Ruidavets JB, Cordelier P, Martins F, Maoret JJ, Bongard V, et al. Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronaryartery disease. Sci Rep. 2017; 7:42916. Folmes KD, Chan AY, Koonen DP, Pulinilkunnil TC, Baczkó I, Hunter BE, Thorn S, Allard MF, Roberts R, Gollob MH, Light PE, Dyck JR : Distinct early signaling events resulting from the expression of the PRKAG2 R302Q mutant of AMPK contribute to increased myocardial glycogen. Circ Cardiovasc Genet. 2009; 2:457-466. Foster CR, Singh M, Subramanian V, Singh K: Ataxia telangiectasia mutated kinase plays a protective role in β-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling. Mol Cell Biochem 2011; 353:13-22. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee : Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129: e28-e292. Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y, Mao Q: MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res 2014;320:200-208. Hardie DG, Ross FA, Hawley SA: AMP-activated protein kinase: a target for drugs both ancient and modern. Chem Biol. 2012; 19:1222-1236. Hasić S, Kiseljaković E, Jadrić R, Radovanović J, Winterhalter-Jadrić M.: Cardiac troponin I: the gold standard in acute myocardial infarction diagnosis. Bosn J Basic Med Sci; 2003; 3: 41-44. Hsu A, Chen SJ, Chang YS, Chen HC, Chu PH: Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int 2014; 2014:418628. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC: MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010; 122:S124-131. Icli B, Dorbala P, Feinberg MW: An emerging role for the miR-26 family in cardiovascular disease. Trends Cardiovasc Med. 2014; 24(6):241-248. Javadov S, Karmazyn M : Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem. 2007; 20:1-22. Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA: Development of cell injury in sustained acute ischemia. Circulation 1990; 82:II2–12. Jeon SM, Chandel NS, Hay N: AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012; 485:661-665. Jia YY, Bao ZW, Wei MF, Zhu JH, Gui L: Aliskiren ameliorates sympathetic nerve sprouting and suppresses the inducibility of ventricular tachyarrhythmia in postinfarcted rat heart. Chin Med J. 2013; 126:4707-4714. Kanamori H, Takemura G, Goto K, Maruyama R, Ono K, Nagao K, Tsujimoto A, Ogino A, Takeyama T, Kawaguchi T, Watanabe T, Kawasaki M, Fujiwara T, Fujiwara H, Seishima M, Minatoguchi S: Autophagy limits acute myocardial infarction induced by permanent coronary artery occlusion. Am J Physiol Heart Circ Physiol. 2011;300:H2261-H2271. Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, Takeyama T, Kawaguchi T, Watanabe T, Morishita K, Kawasaki M, Mikami A, Fujiwara T, Fujiwara H, Seishima M, Minatoguchi S : Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol. 2013; 182:701-713. Kang MR, Park SK, Lee CW, Cho IJ, Jo YN, Yang JW, Kim JA, Yun J, Lee KH, Kwon HJ, Kim BW, Lee K, Kang JS, Kim HM : Widdrol induces apoptosis via activation of AMP-activated protein kinase in colon cancer cells. Oncol Rep. 2012;27:1407-1412. Karuppagounder SS, Basso M, Sleiman SF, Ma TC, Speer RE, Smirnova NA, Gazaryan IG, Ratan RR : In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation. J Neurosci Res. 2013; 91:1066-1075. Khanna KK, Lavin MF, Jackson SP, Mulhern TD: ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 2001;8:1052-1065. Kimata M, Matoba S, Iwai-Kanai E, Nakamura H, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Mita Y, Okigaki M, Ikeda K, Tatsumi T, Matsubara H: P53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress. Am J Physiol Heart Circ Physiol 2010;299:H1908-1916. Kitsis RN, Peng CF, Cuervo AM : Eat your heart out. Nat Med. 2007;13:539-541. Konstantinidis K, Whelan RS, Kitsis RN : Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol. 2012;32:1552-1562. Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, Maegdefessel L, Kundu RK, Quertermous T, Tsao PS, Spin JM: MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol 2011;226:1035-1043. Li C, Chen X, Huang J, Sun Q, Wang L: Clinical impact of circulating miR-26a, miR-191, and miR-208b in plasma of patients with acute myocardial infarction. Eur J Med Res 2015;20:58. Liang H, Xu C, Pan Z, Zhang Y, Xu Z, Chen Y, Li T, Li X, Liu Y, Huangfu L, Lu Y, Zhang Z, Yang B, Gitau S, Lu Y, Shan H, Du Z: The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. Mol Ther 2014;22:1122-1133. Liang CJ, Shen WC, Chang FB, Wu VC, Wang SH, Young GH, Tsai JS, Tseng YC, Peng YS, Chen YL: Endothelial progenitor cells derived from wharton's jelly of human umbilical cord attenuate ischemic acute kidney injury by increasing vascularization and decreasing apoptosis, inflammation, and fibrosis. Cell Transplant 2015;24:1363-1377. Lin Y, Sibanda VL, Zhang HM, Hu H, Liu H, Guo AY: MiRNA and TF co-regulatory network analysis for the pathology and recurrence of myocardial infarction. Sci Rep 2015;13:9653-9661. Liu CW, Sung HC, Lin SR, Wu CW, Lee CW, Lee IT, Yang YF, Yu IS, Lin SW, Chiang MH, Liang CJ, Chen YL: Resveratrol attenuates ICAM-1 expression and monocyte adhesiveness to TNF-α-treated endothelial cells: evidence for an anti-inflammatory cascade mediated by the miR-221/222/AMPK/p38/NF-κB pathway. Sci Rep 2017;7:44689. Liu YC, Zou XB, Chai YF, Yao YM.: Macrophage polarization in inflammatory diseases. Int J Biol Sci 2014;1:520-529 Lockshin RA, Zakeri Z.: Caspase-independent cell deaths. Curr Opin Cell Biol 2002;14:727–733. Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M, Musacchio E, Barbieri M, Mauro C, Mosca N, Solimene F, Mottola MT, Russo A, Rossi F, Paolisso G, D'Amico M: Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail 2013;15:1277-1288. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J : Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007; 100:914-922. Matsui Y, Kyoi S, Takagi H, Hsu CP, Hariharan N, Ago T, Vatner SF, Sadoshima J : Molecular mechanisms and physiological significance of autophagy during myocardial ischemia and reperfusion. Autophagy. 2008; 4:409-415. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, LewseyJ:Aliskiren Observationof Heart Failure Treatment(ALOFT)Investigators : Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1:17-24. McMurray JJ, Dickstein K, Køber LV: Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016; 21:1521-32. Miao J, Wang L, Zhang X, Zhu C, Cui L, Ji H, Liu Y, Wang X: Protective Effect of Aliskiren in Experimental Ischemic Stroke: Up-Regulated p-PI3K, p-AKT, Bcl-2 Expression, Attenuated Bax Expression. Neurochem Res. 2016; 41:2300-2310. Mihaylova MM, Shaw RJ: The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011; 13:1016-1023. Moe GW, Marín-García J: Role of cell death in the progression of heart failure. Heart Fail Rev. 2016; 21:157-167. Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG,Wilke CA, Flaherty KR, Martinez FJ, Tsui JL, Sheppard D, Baralle FE, Toews GB, White ES.: An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:638–645. Narbonne P, Roy R: Caenorhabditis elegans dauers need LKB1/AMPK to ration lipid reserves and ensure long-term survival. Nature. 2009;457:210-214. Nemchenko A, Chiong M, Turer A, Lavandero S, Hill JA : Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol. 2011;51:584-93. Nishida K, Yamaguchi O, Otsu K : Crosstalk between autophagy and apoptosis in heart disease. Circ Res. 2008; 103:343-351. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med. 2008;358: 2433-2466. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators : Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 6:2204-2213. Peng J, He X, Zhang L, Liu P.: MicroRNA 26a protects vascular smooth muscle cells against H2O2 induced injury through activation of the PTEN/AKT/mTOR pathway. Int J Mol Med 2018; 42: 1367-1378. Qi D, Young LH: AMPK: energy sensor and survival mechanism in the ischemic heart. Trends Endocrinol Metab. 2015; 26:422-429. Ramirez TA, Iyer RP, Ghasemi O, Lopez EF, Levin DB, Zhang J, Zamilpa R, Chou YM, Jin YF, Lindsey ML: Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. J Mol Cell Cardiol. 2014; 72:326-35. Rotman G, Shiloh Y: ATM: from gene to function. Hum Mol Genet 1998; 7:1555-1563. Rubiś P, Totoń-Żurańska J, Wiśniowska-Śmiałek S, Holcman K, Kołton-Wróż M, Wołkow P, Wypasek E, Natorska J, Rudnicka-Sosin L, Pawlak A, Kozanecki A, Podolec P: Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy. Int J Cardiol 2017; 15:201-206. Santini D, Abbate A, Scarpa S, Vasaturo F, Biondi-Zoccai GG, Bussani R, De Giorgio F, Bassan F, Camilot D, Di Marino MP, Feroce F, Baldi F, Silvestri F, Crea F, Baldi A.: Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction. J Clin Pathol 2004; 57:1321–1324. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100:416-424. Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27:5959-5974. Sethupathy P, Megraw M, Hatzigeorgiou AG: A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006; 3:881-886. Shah AM, Shin SH, Takeuchi M, Skali H, Desai AS, Køber L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, Keefe D, McMurray JJ, Pfeffer MA, Solomon SD: Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012; 14:185–192. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators : Effect of the direct Renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530-537. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators : Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227-1234. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ.: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944–1949. Suh JH, Choi E, Cha MJ, Song BW, Ham O, Lee SY, Yoon C, Lee CY, Park JH, Lee SH, Hwang KC: Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3β protein expression. Biochem Biophys Res Commun 2012; 423:404-410. Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, Grieco D, Vinciguerra M, Agnese S, Jüngel A, Distler O, Musti AM, Gabrielli A, Avvedimento EV: Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal 2014; 7:ra84. Talman V, Ruskoaho H: Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration: Cell Tissue Res 2016; 365:563-581. Teringova E, Tousek P. Apoptosis in ischemic heart disease: J Transl Med 2017; 15:87. Tian Y, Liu Y, Wang T, Zhou N, Kong J, Chen L, Snitow M, Morley M, Li D, Petrenko N, Zhou S, Lu M, Gao 5, Koch WJ, Stewart KM, Morrisey EE: A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. Sci Transl Med 2015; 7:279ra38. Traganos F, Darzynkiewicz Z: Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol. 1994; 41:185-194. Tucka J, Bennett M, Littlewood T: Cell death and survival signalling in the cardiovascular system. Front Biosci. 2012;17:248-261. van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH : Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 2010;28:2145-55. Vessoni AT, Filippi-Chiela EC, Menck CF, Lenz G : Autophagy and genomic integrity. Cell Death Differ. 2013;20:1444-1454. Wang SH, Liang CJ, Wu JC, Huang JJ, Chien HF, Tsai JS, Yen YS, Tseng YC, Lue JH, Chen YL : Pigment epithelium-derived factor reduces the PDGF-induced migration and proliferation of human aortic smooth muscle cells through PPARγ activation. Int J Biochem Cell Biol. 2012;44:280-289. Wei C, Kim IK, Kumar S, Jayasinghe S, Hong N, Castoldi G, Catalucci D, Jones WK, Gupta S: NF-κB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol 2013;228:1433-1442. Weng LQ, Zhang WB, Ye Y, Yin PP, Yuan J, Wang XX, Kang L, Jiang SS, You JY, Wu J, Gong H, Ge JB, Zou YZ: Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin. 2014; 35:1005-1014. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschöpe C: Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075. Xiao Q, Yang Y, Qin Y, He YH, Chen KX, Zhu JW, Zhang GP, Luo JD: AMP-activated protein kinase-dependent autophagy mediated the protective effect of sonic hedgehog pathway on oxygen glucose deprivation-induced injury of cardiomyocytes. Biochem Biophys Res Commun. 2015;13:419-425. Xie J, Zhang Q, Zhu T, Zhang Y, Liu B, Xu J, Zhao H.: Substrate stiffness-regulated matrix metalloproteinase output in myocardial cells and cardiacfibroblasts: implications for myocardial fibrosis. Acta Biomater 2014;10:2463-2472. Yan X, Gan Y, Chen H, Liu G, Hu S, Zhou J: The miRNA Expression Profile in Acute Myocardial Infarct Using Sheep Model with Left Ventricular Assist Device Unloading. Biomed Res Int 2017;2017:4352450. Yang DQ, Kastan MB: Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2000;2:893-898. Yao L, Lv X, Wang X: MicroRNA 26a inhibits HMGB1 expression and attenuates cardiac ischemia-reperfusion injury. J Pharmacol Sci 2016;131:6-12. Yin KJ, Chen SD, Lee JM, Xu J, Hsu CY: ATM gene regulates oxtgen-glucose deprivation-induced nuclear factor-kappaB DNA-binding activity and downstream apoptotic cascade in mouse cerebrovascular endothelial cells. Stroke 2002; 33:2471-2477. Yoshida M, Shiojima I, Ikeda H, Komuro I: Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosispathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 2009; 47:698-705. Zamilpa R, Lindsey ML: Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol 2010; 48:558-563. Zhan H, Aizawa K, Sun J, Tomida S, Otsu K, Conway SJ, Mckinnon PJ, Manabe I, Komuro I, Miyagawa K, Nagai R, Suzuki T: Ataxia telangiectasia mutated in cardiac fibroblasts regulates doxorubicin-induced cardiotoxicity. Cardiovasc Res 2016; 110:85-95. Zhang JT, Chen KP, Guan T, Zhang S : Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2015; 2:1963-1971. Zhang W, Zhao G, Hu X, Wang M, Li H, Ye Y, Du Q, Yao J, Bao Z, Hong W, Fu G, Ge J, Qiu Z: Aliskiren-attenuated myocardium apoptosis via regulation of autophagy and connexin-43 in aged spontaneously hypertensive rats. J Cell Mol Med. 2014; 18:1247-1256. Zhang Y, Qin W, Zhang L, Wu X, Du N, Hu Y, Li X, Shen N, Xiao D, Zhang H, Li Z, Zhang Y, Yang H, Gao F, Du Z, Xu C, Yang B: MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis. Sci Rep 2015; 5:9401. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73508 | - |
dc.description.abstract | 心肌梗塞(myocardial infarction)已經成為工業化與發展中國家的重要的健康問題,也是主要致死原因之一。雖然細胞凋亡已經被證實在心肌梗塞中扮演不可或缺的角色,而且也是心臟再塑化主要的原因之一,但是其詳細的機制以及有效的治療方法仍然尚未被釐清。Aliskiren是一種腎素的抑制劑(direct renin inhibitor, DRI),一種新開發的降血壓藥,近年來許多研究指出aliskiren可以減緩心肌梗塞後心臟傷害的情形,但詳細機制仍尚未明瞭。同時miR-26a在心肌梗塞中扮演的角色仍然存在許多爭議。本文主要目的在探討經過OGD (oxygen glucose deprivation)處理的H9c2心肌細胞以及在心肌梗塞模式的小鼠,aliskiren及miR-26a對心肌缺氧後對心臟保護的影響。
本論文分成兩個部分,第一部分,我們使用8到12週大的C57BL/6小鼠,藉由結紮心臟的左前降支冠狀動脈(left anterior descending coronary artery, LAD)做為心肌梗塞的動物模式。以皮下注射的方式給予aliskiren,並使用心臟超音波進行掃瞄,測量縮短分率,以評估小鼠的心臟功能。同時採用西方墨點法及免疫組織染色法,觀察aliskiren對心肌梗塞後心臟傷害相關蛋白表現的影響。在細胞模式中,我們使用OGD處理後的H9c2細胞給予aliskiren後,探討該治療是否有保護心肌細胞的能力以及其相關機轉。第一部分的結果顯示,在心肌梗塞動物模式中,aliskiren治療組降低cleaved caspase-3蛋白量、並提高LC3B-II的能力,同時藉由電子顯微鏡的檢測,證明aliskiren有增加自噬作用的能力。此外,我們利用H9c2細胞的缺氧缺糖模式,證實aliskiren不但能減少細胞凋亡、增加粒線體膜電位,也可以藉由增加自噬小體(autophagosome)的形成來增加自噬作用。我們也證實aliskiren增加心肌細胞的存活率是透過增加AMPK蛋白量的表現而增加自噬作用。 第二部分,我們同樣使用小鼠心肌梗塞的動物模式,以尾靜脈或心臟注射的方式給予miR-26a,並使用心臟超音波進行掃瞄測量fractional shortening (FS %),以評估小鼠的心臟功能。同時採用西方墨點法及免疫組織染色法,觀察miR-26a對心肌梗塞後心臟傷害的保護效果以及與細胞凋亡相關蛋白的表現。同時我們想探討miR-26a所調控的標靶基因是否參與其中,我們進一步利用生物資訊的分析,找出其標靶基因為ataxia–telangiectasia mutated (ATM),並在OGD處理後的H9c2細胞的模式中,給予miR-26a後,探討該治療是否有保護心肌細胞的能力以及與ATM蛋白的相關機轉。第二部分的結果顯示,我們利用螢光素酶檢測法(Luciferase Assay)證實miR-26a確實有調控其標靶基因ATM的能力,在OGD處理的心肌細胞中也能減少細胞凋亡以及其相關蛋白的表現量。我們也證實在心肌梗塞一天的小鼠中,miR-26a可以有效的減少ATM的表現以及減緩心肌細胞凋亡的狀況,而且在手術十四天後的老鼠中亦能改善其心臟功能,減少心臟纖維化的狀況以及collagen type I和connective tissue growth factor (CTGF)的表現量。此結果顯示aliskiren及miR-26a在細胞及動物實驗中皆可降低caspase-3的表現以及心臟纖維化的狀況。aliskiren改善缺氧缺糖引起心肌細胞的傷害是透過AMPK來活化自噬作用所致。而miR-26a則是透過調控標靶基因-ATM來控制。因此,aliskiren及miR-26a提供了一種治療心肌梗塞藥物的新選擇。 | zh_TW |
dc.description.abstract | Myocardial infarction (MI) is a major health problem and the leading cause of death and disability in both industrialized and developing nations. Although cell apoptosis has been proposed to play the important role in the progression of MI and cardiac remodeling, its exact triggering mechanism is still unclear and the efficiency of the therapeutic approach is not available. Aliskiren, a direct renin inhibitor (DRI), was developed as an antihypertensive drug. The previous studies have indicated that aliskiren treatment attenuated cardiac remodeling after MI. However, the mechanism remained unclear. In addition, the role of miR-26a in MI is diverse and still controversial. The purpose of this study was to investigate the protective effects of aliskiren and miR-26a on oxygen glucose deprivation (OGD)-treated H9c2 cardiomyocytes and mouse model of MI.
The doctoral dissertation is divided into two parts. In the first part, we used male C57BL/6 mice at age of 8-12 weeks and the left anterior descending coronary artery (LAD) was ligated as the MI animal model. In addition, the mice were injected subcutaneously with or without aliskiren. The cardiac function was evaluated by echocardiography. The percentages of fractional shortening (FS%) were measured. We investigated the effects of aliskiren on MI-induced injury and the related proteins were examined by western blot and immunohistochemical staining. Futhermore, we explored whether the aliskiren treatment protected cardiomyocytes and its related mechanisms in OGD-treated H9c2 cells. Aliskiren treatment reduced the protein expression of caspase-3 in MI mice. Moreover, aliskiren increased autophagy as demonstrated by LC3B-II expression and transmission electron microscopy. In OGD-treated H9c2 cells, aliskiren decreased apoptosis and improved mitochondrial membrane potential as well as increased autophagy via increased autophagosome formation. We also found that aliskiren induced cardiomyocyte survival through AMP-activated protein kinase (AMPK)-dependent autophagy. In the second part, we evaluated whether miR-26a ameliorated MI-induced injury. The miR-26a was injected into the myocardium or the tail vein after MI. The cardiac function was evaluated by echocardiography. The percentages of FS% were measured. We investigated that the effects of miR-26a on MI-induced injury and the related protein were examined by western blot and immunohistochemical staining. In addition, we examined whether the target gene of miR-26a participate in the pathway about MI-induced injury. Further analysis identified that ataxia–telangiectasia mutated (ATM) was a target gene for miR-26a based on a bioinformatics analysis. In addition, we explored whether the miR-26a treatment protected cardiomyocytes from OGD-induced injury and its mechanisms related to ATM. The luciferase assay showed that miR-26a overexpression significantly decreased the luciferase activity of the ATM 3′-UTR. MiR-26a significantly reduced ATM expression, apoptosis and apoptosis-related protein in OGD-treated H9c2 cells. MiR-26a effectively reduced ATM expression and cardiac apoptosis at day 1 after MI. Furthermore, we demonstrated that overexpression of miR-26a improved cardiac function and reduced cardiac fibrosis, which decreased both collagen type I and connective tissue growth factor (CTGF) expression in mice at day 14 after MI. Taken together, these results suggest that aliskiren and miR-26a reduced caspase-3 expression and improved cardiac fibrosis under in vitro and in vivo conditions. Aliskiren improved ischemia- and OGD-induced cardiac injury through activation AMPK-depentent autophagy. Moreover, miR-26a alleviated the development of MI by regulating ATM. Therefore, aliskiren and miR-26a may represent novel therapeutic agents in ischemic cardiac diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:38:59Z (GMT). No. of bitstreams: 1 ntu-108-D01446001-1.pdf: 4656674 bytes, checksum: 18dda0e68842de6fbee03bbc92b61cdb (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 目錄
口試委員審定書 誌謝 中文摘要 I 英文摘要 III 簡介 V PART I 1 中文摘要 1 英文摘要 2 第一章 簡介 4 第二章 材料與方法 6 2.1. In vivo mouse model of myocardial infarction 6 2.2. Physiological assessments of cardiac function 6 2.3. Blood pressure measurements 7 2.4. Specimen collection and morphometric analysis 7 2.5. Real-time PCR of fresh tissues 7 2.6. Immunohistochemistry 8 2.7. Measurements of angiotensin (Ang) II in cardiac tissues 8 2.8. Cell culture and oxygen glucose deprivation (OGD)-induced injury in vitro 8 2.9. Cell viability assay 9 2.10 Flow cytometric analysis 9 2.11 Identification of apoptosis by terminal dUTP nick end-labeling (TUNEL) staining 10 2.12 Immunostaining for LC3B and p-AMPK 10 2.13 Detection of autophagosomes by staining with acridine orange 10 2.14 Western blotting 11 2.15 Detection of the mitochondrial membrane potential by JC-1 staining 11 2.16 Transmission electron microscopy 12 2.17. Statistical analysis 12 第三章 結果 13 3.1. Aliskiren treatment improves cardiac function and morphology in MI mice 13 3.2. Aliskiren treatment reduces apoptosis and increases autophagy in MI mice 14 3.3. Aliskiren treatment increases cell viability in H9c2 cells under OGD challenge 15 3.4. Aliskiren attenuates the OGD-induced decrease in the mitochondrial transmembrane potential (MTP) in H9c2 cells 17 3.5. Aliskiren increases cell viability via the AMPK pathway in H9c2 cells during OGD-induced injury 17 第四章 討論 19 附圖 25 Figure 1: Aliskiren treatment improves cardiac function in MI mice 25 Figure 2: Aliskiren treatment improves morphology in MI mice 26 Figure 3: Aliskiren adminstration strongly decreases apoptosis and increases autophagy in MI mice. 28 Figure 4: Aliskiren treatment improves cardiac ultrastructure and upregulates the autophagosomes in cardiomyocytes of MI mice by transmission electron microscopy 30 Figure 5: Aliskiren increases cell viability in oxygen glucose deprivation (OGD)-treated H9c2 cells via the upregulation of autophagosome formation 33 Figure 6: Aliskiren attenuates OGD-induced the reduction of mitochondrial transmembrane potential (MTP) and recovers mitochondrial intact in H9c2 cells. 34 Figure 7: Aliskiren increases autophagy-induced cell viability by activation of the AMPK pathway in OGD-treated H9c2 cells. 36 Table 1 MI mice characteristics of the echocardiographic analysis 37 Table 2 LV classification of heart section 37 Table 3 Blood pressure in sham-operated mice 37 PART II 39 中文摘要 39 英文摘要 40 第一章 簡介 41 第二章 材料與方法 44 2.1 Patients 44 2.2 Analysis of miRNA expression profiling in plasma from STEMI patients by TaqMan Open Array Human MicroRNA panel. 44 2.3 MiRNA targets and pathway analysis 45 2.4 Validation of plasma microRNA by real-time polymerase chain reaction 46 2.5 Cell culture and oxygen glucose deprivation (OGD)-induced injury in vitro 46 2.6 Immunofluorescent staining 47 2.7 The transfection of miRNA mimic and RNA interference (RNAi) 47 2.8 Luciferase reporter assays 48 2.9 In vivo mouse model of myocardial infarction 48 2.10 In vivo delivery of miR-26a mimic 49 2.11 Echocardiography 49 2.12 Specimen collection, immunohistochemistry and Masson's trichrome staining 50 2.13 Identification of apoptosis by terminal dUTP nick end-labeling (TUNEL) staining 50 2.14 RNA extraction and Real-time PCR 51 2.15 Western blot analysis 51 2.16 The measurement of collagen content 52 2.17 Statistical analysis 52 第三章 結果 54 3.1 The low plasma miR-26a is highly associated with cardiac injury markers in STEMI patients 54 3.2 MiR-26a reduced apoptosis via targeting ATM in OGD-treated H9c2 cardiomyocytes 55 3.3 The decreased miR-26a expression and increased ATM expression in the infarct zone in mice at 1 day after MI 57 3.4 Enhancement of miR-26a attenuated cardiac fibrosis and cardiac function in mice at 14 days of MI 59 第四章 討論 61 附圖 69 Figure 1 Heat map of miRNA microarray 69 Figure 2: MiRNA analysis between STEMI patients and non-CHD patients 70 Figure 3: The low miR-26a plasma level is highly correlated with markers for cardiac injury in STEMI patients. 71 Figure 4: The expression of p-p53 and cleaved caspase-3 and TUNEL assay in OGD-treated H9c2 cells 72 Figure 5: The expression of miR-26a in OGD-treated H9c2 cells 73 Figure 6: Analysis of the conserved putative genes of miR-26a revealed several enriched KEGG pathways. 74 Figure 7: miR-26a is a critical regulator of ATM expression. 75 Figure 8: MiR-26a reduced apoptosis in OGD-treated H9c2 cardiomyocytes. 78 Figure 9: The shATM transfection resulted in an augmentation of miR-26a expression as demonstrated by real-time PCR. 79 Figure 10: The shATM transfection decreased apoptosis in OGD-treated H9c2 cells 81 Figure 11: MiR-26a attenuated OGD-induced apoptosis through the downregulation of ATM. 83 Figure 12: The levels of miR-26a expression were presented in different zones in ischemial heart in mice after 1 day. 84 Figure 13: The levels of cleaved caspase-3 expression and TUNEL assay were presented in different zones in ischemial heart in mice after 1 day. 86 Figure 14: The levels of ATM were presented in different zones in ischemial heart in mice after 1 day. 87 Figure 15: MiR-26a mimic significantly attenuated apoptosis and ATM expression in mice at 1day of MI 89 Figure 16: The cardiac function was evaluated by echocardiographic assessment in mice at 14day of MI. 90 Figure 17: MiR-26a mimic attenuated cardiac fibrosis in mice at 14 days of MI. 92 Figure 18: The expression of ATM was present in the infarct zone and border zone in mice at 14day of MI by immunohistochemistry. 93 Figure 19: MiR-26a mimic significantly reduced the expression of collagen type I and CTGF in OGD-treated cardiomyocytes. 94 Figure 20: The shATM significantly reduced the collagen type I and CTGF expression in OGD-treated cardiomyocytes 95 Figure 21: Schematic diagram of myocardial infarction induced signaling and protective effect of miR-26a 96 Table 1 Baseline characteristics of study population 97 Table 2 The KEGG pathways analysis of pontential targets of the miR-26a 98 Table 2 The KEGG pathways analysis of pontential targets of the miR-26a 98 Table 3 The characteristics of the echocardiographic analysis in MI mice at day 1 99 Table 4 The characteristics of the echocardiographic analysis in MI mice at day 14 100 參考資料 101 結論 114 | |
dc.language.iso | en | |
dc.title | 研究aliskiren和miR-26a對心肌梗塞引發傷害之保護效益及其相關機轉 | zh_TW |
dc.title | To study the protective effects of aliskiren and miR-26a on myocardial infarction-induced injury and the related mechanisms | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 江美治(Meei-Jyh Jiang),王懷詩(Hwai-Shi Wang),李江文(Chiang-Wen Lee),王淑慧(SHU-HUEI WANG),李宗玄(Tzong-Shyuan Lee) | |
dc.subject.keyword | aliskiren,miR-26a,ataxia–telangiectasia mutated (ATM),細胞凋亡,纖維化,心肌梗塞, | zh_TW |
dc.subject.keyword | aliskiren,miR-26a,ataxia–telangiectasia mutated (ATM),apoptosis,fibrosis,myocardial infarction (MI), | en |
dc.relation.page | 114 | |
dc.identifier.doi | 10.6342/NTU201900449 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-03-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 4.55 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。